ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

2004 • 10,779 citations

The biology of VEGF and its receptors

2003 • 9,272 citations

Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid

1983 • 3,942 citations

Vascular-specific growth factors and blood vessel formation

2000 • 3,667 citations

Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.

1995 • 3,139 citations

Epidermal growth factor-related peptides and their receptors in human malignancies

1995 • 2,689 citations

Molecular regulation of vessel maturation

2003 • 2,446 citations

Role of angiogenesis in tumor growth and metastasis

2002 • 2,412 citations

Role of angiogenesis in tumor growth and metastasis

2002 • 2,310 citations

Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway

1998 • 1,963 citations

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

2004 • 1,935 citations

Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

2000 • 1,310 citations

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

1999 • 1,248 citations

Protein Kinase Inhibitors: Insights into Drug Design from Structure

2004 • 1,180 citations

A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

2001 • 988 citations

Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.

1999 • 866 citations

VEGF-receptor signal transduction

2003 • 846 citations

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

2002 • 784 citations

Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies

2003 • 651 citations

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.

1993 • 645 citations

Clinical Implications of Circulating Angiogenic Factors in Cancer Patients

2001 • 599 citations

Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.

1999 • 599 citations

Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis.

1995 • 598 citations

Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas.

1993 • 564 citations

Vascular Endothelial Growth Factor as a Target for Anticancer Therapy

2004 • 564 citations

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

2002 • 554 citations

Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.

1993 • 534 citations

Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

2000 • 505 citations

VEGF Receptor Signal Transduction

2001 • 496 citations

Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possibleIn vivo regulatory mechanisms

1994 • 464 citations

Vascular Growth Factors and Lymphangiogenesis

2002 • 412 citations

Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

2004 • 341 citations

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

2003 • 318 citations

Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors

2002 • 308 citations

Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients.

2000 • 264 citations

Transforming growth factor-alpha -induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation

1997 • 256 citations

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

2004 • 239 citations

Oncogenes and Angiogenesis: Signaling Three-Dimensional Tumor Growth

2000 • 225 citations

Molecular Mechanisms of RET Activation in Human Cancer

2002 • 171 citations

Expression of vascular endothelial growth factor, hypoxia inducible factor 1α, and carbonic anhydrase IX in human tumours

2004 • 156 citations

Effect of the vascular endothelial growth factor receptor‐2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice

2002 • 142 citations

ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy

2004 • 134 citations

Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours

2003 • 124 citations

Small In-Frame Deletion in the Epidermal Growth Factor Receptor as a Target for ZD6474

2004 • 120 citations

ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer

2004 • 110 citations

Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.

2003 • 103 citations

Expression of Vascular Endothelial Growth Factor Receptor-3 by Lymphatic Endothelial Cells Is Associated with Lymph Node Metastasis in Prostate Cancer

2004 • 103 citations

Impact of Vascular Endothelial Growth Factor-C and -D Expression in Human Pancreatic Cancer

2004 • 102 citations

Therapies directed at vascular endothelial growth factor

2002 • 91 citations

Vascular endothelial growth factor‐C expression correlates with lymph node localization of human melanoma metastases

2003 • 87 citations

Drug inhibition of angiogenesis

2002 • 72 citations

Vascular endothelial growth factor‐C (VEGF‐C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder

2005 • 63 citations

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)‐sensitive and resistant xenograft models

2004 • 60 citations

Immunodetection and quantification of vascular endothelial growth factor receptor‐3 in human malignant tumor tissues

2004 • 47 citations

The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma

2004 • 41 citations

Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor

2005 • 40 citations

P-359 Results from a phase I study of the oral VEGF receptor tyrosine kinase inhibitor ZD6474, in patients with solid tumors

2003 • 33 citations

Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model

2007 • 32 citations

Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation

2004 • 29 citations

Animal Systems for Translational Research in Radiation Oncology

1999 • 27 citations

ZD6474, a small molecule targeting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer

2004 • 13 citations

Augmentation of radiation response with the VEGFR-tyrosine kinase inhibitor ZD6474

2004 • 7 citations

The VEGF signaling inhibitors ZD6474 and AZD2171 compromise hemodynamic parameters in an SW620 human colon tumor model: An analysis using perfusion-permeability dynamic contrast-enhanced magnetic resonance imaging (pp-DCE-MRI)

2004 • 6 citations

The VEGF receptor tyrosine kinase inhibitor ZD6474 significantly reduces intestinal tumor burden in the Min mouse

2004 • 2 citations

The vascular-targeting agent, ZD6126, and the antiangiogenic agent, ZD6474, inhibit liver metastases via differential effects on metastatic vasculature.

2003 • 2 citations

Targeted therapy against VEGF and EGF receptor signaling with ZD6474 blocks angiogenesis and inhibits the growth and dissemination of orthotopic human lung cancer in mice.

2003 • 1 citations